Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 9/20 | 0.60 |
| ▸ | AXL | P30530 | 8/20 | 0.60 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.50 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.50 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.50 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.50 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.50 |
| ▸ | MET | P08581 | 4/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21779419 | 0.90 | MERTK (0.61) | MERTKAXLACVR1BMPR1BBMPR1A | |
| SCHEMBL18611887 | 0.85 | MERTK (0.59) | MERTKAXLACVR1BMPR1BBMPR1A | |
| SCHEMBL18616305 | 0.85 | AXL (0.59) | MERTKAXLACVR1BMPR1BBMPR1A | |
| SCHEMBL21779412 | 0.83 | AXL (0.56) | MERTKAXLACVR1BMPR1BBMPR1A | |
| SCHEMBL18615387 | 0.80 | MERTK (0.65) | MERTKAXLACVR1BMPR1BBMPR1A | |
| SCHEMBL18580395 | 0.77 | AXL (0.89) | MERTKAXL | |
| SCHEMBL18579601 | 0.77 | MERTK (1.00) | MERTKAXL | |
| SCHEMBL18612199 | 0.77 | L3MBTL3 (0.59) | MERTKAXLMETLRRK2 | |
| SCHEMBL18612197 | 0.76 | MERTK (0.59) | MERTKAXLACVR1BMPR1BBMPR1A | |
| SCHEMBL18611892 | 0.75 | MERTK (0.55) | MERTKAXLMETPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002353-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2023-01-05 | — | — | US | disclosed |
| US-10947215-B2 | Heteroaryl compounds and their use as therapeutic drugs | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2021-03-16 | — | — | US | disclosed |
| EP-3344613-B1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2020-03-04 | — | — | EP | disclosed |
| US-20190119252-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2019-04-25 | — | — | US | disclosed |
| WO-2017039331-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10947215-B2 | Heteroaryl compounds and their use as therapeutic drugs | MERTK, ERBB2, SRC | MERTK 1/4885AXL 30/4885ACVR1 2153/4885 |
| US-20190119252-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | MERTK, ERBB2, SRC | MERTK 1/4885AXL 30/4885ACVR1 2153/4885 |
| US-20230002353-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | MERTK, ERBB2, SRC | MERTK 1/4885AXL 30/4885ACVR1 2153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.